Blinatumomab Assigned Breakthrough Therapy Designation to Treat Acute Lymphoblastic Leukemia
the Cancer Therapy Advisor take:
Amgen has announced that the U.S. Food and Drug Administration (FDA) has designated its drug, blinatumomab, breakthrough therapy status. Blinatumomab is an investigational bispecific T-cell engager (BiTE) antibody currently being studied for the treatment of adults with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
The FDA granted this status based on the results of Amgen's phase 2 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting. In the study, 189 adults with Ph-negative relapsed/refractory B-precursor ALL were treated with blinatumomab.
Of those, 43% experienced a complete response and relapse-free survival duration was 5.9 months. Overall survival duration was 6.1 months. The most common grade 3 adverse events observed were febrile neutropenia, neutropenia, and anemia.
A phase 3 study testing blinatumomab in patients with Ph- ALL is currently underway. According to the American Cancer Society, about 6,000 adults will be diagnosed with ALL in 2014, and nearly 1,500 will die from the disease.
Amgen has announced that the FDA has designated its drug, blinatumomab, Breakthrough Therapy status.
The FDA states that Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer